|1.||Centers for Disease Control and Prevention (CDC): 24 articles (02/2015 - 03/2001)|
|2.||Halperin, Scott A: 16 articles (09/2015 - 05/2002)|
|3.||Edwards, Kathryn M: 8 articles (04/2014 - 06/2005)|
|4.||He, Qiushui: 8 articles (04/2012 - 07/2004)|
|5.||Okada, Kenji: 7 articles (10/2015 - 08/2002)|
|6.||Cherry, James D: 7 articles (06/2015 - 03/2002)|
|7.||Friedland, Leonard R: 7 articles (02/2015 - 04/2006)|
|8.||Bock, Hans L: 7 articles (03/2010 - 10/2003)|
|9.||Marshall, Helen: 6 articles (12/2015 - 03/2010)|
|10.||Halperin, S A: 6 articles (11/2015 - 01/2000)|
|1.||Whooping Cough (Pertussis)
12/01/2006 - "Administering all 5 doses of pertussis vaccine and the fifth dose at age 5 years with at least 36 months between the fourth and fifth doses provided the best protection against pertussis among children and adolescents in this outbreak."
07/15/2002 - "Thus, even after partial vaccination, acellular pertussis vaccine is highly effective in preventing hospitalizations for pertussis."
03/01/1991 - "These findings suggest that, since its introduction, the whole-cell pertussis vaccine produced in South Africa has been highly effective in controlling whooping cough. "
05/01/1985 - "The incidence of pertussis has been dramatically reduced in many areas of the world over the past 25 years by the use of pertussis vaccine. "
01/01/1997 - "Household studies in the two recently concluded Swedish pertussis vaccine efficacy trials demonstrated that one monocomponent and one five-component candidate acellular pertussis vaccine had reasonably good protective efficacy against clinically typical pertussis after household exposure. "
12/01/1990 - "The subjects consisted of 56 volunteers (20-31 years of age) who had received regular inoculations of diphtheria and pertussis vaccine (I and II or III phases). "
01/01/1962 - "[The morphology of the vaccination process in guinea pigs inoculated with diphtheriapertussis, pertussis vaccine and diphtheria anatoxin]."
10/01/2013 - "In this randomized, blinded, controlled study, volunteers received either 3 doses of CYD-TDV (n = 401) or placebo as first and second injection and tetanus/diphtheria/acellular pertussis vaccine as third injection (n = 199) at 0, 6 and 12 months. "
09/21/2012 - "A phase III, randomized controlled study to assess the safety and immunogenicity of a semi-synthetic diphtheria, tetanus and whole-cell pertussis vaccine in Indian infants."
09/01/2008 - "The objective of this study was to determine the feasibility of tetanus, diphtheria, and acellular pertussis vaccine administration to parents in a tertiary care, level III NICU and to measure its effect on vaccination rates among parents of this high-risk population. "
07/18/2013 - "However, the WHO-estimated immunization coverage of 88% for 3 doses of Diptheria-Tetanus-Pertussis vaccine in Pakistan is likely an over-estimate. "
01/01/2013 - "HEU demonstrated stronger pertussis vaccine responses, developing protective titers 1 year earlier than HUU patients, and maintained higher anti-tetanus titers at 24 months of age. "
02/03/2007 - "Pneumococcal vaccination at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262,000 deaths per year (7%) in children aged 3-29 months in the 72 developing countries studied, thus averting 8.34 million disability-adjusted life years (DALYs) yearly. "
12/01/2003 - "All monkeys were inoculated with diptheria, tetanus, and acellular pertussis vaccine at 5 weeks of age to simulate human infant vaccination schedules. "
01/01/1969 - "Histological changes in the heart of animals, induced by immunization with heart tissue homogenate and diptheria-tetanus-pertussis vaccine."
05/15/2011 - "Finally, using a murine respiratory infection model, we demonstrated that LT can act as a highly effective adjuvant for a pertussis vaccine, promoting Ag-specific Th17 cells and protection against Bordetella pertussis challenge, which was significantly reduced in IL-17-defective mice. "
09/01/2012 - "Understanding the immune responses that explain why infants require multiple doses of pertussis vaccine to achieve protection against infection is a high priority. "
12/01/2010 - "However, this decrease exists only for Bordetella pertussis infections, as the incidence of Bordetella parapertussis confirmed cases has remained stable, suggesting that pertussis-vaccine-induced immunity is not protective against parapertussis, as expected. "
08/01/1998 - "The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in respiratory mouse model."
02/01/1998 - "The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model."
03/01/2000 - "To assess the diagnostic sensitivity and specificity of a Bordetella pertussis polymerase chain reaction (PCR) assay using nasopharyngeal (NP) specimens from subjects with cough illnesses participating in a large pertussis vaccine efficacy trial. "
10/01/1995 - "In a large pertussis vaccine efficacy trial in Germany, vaccinees and/or their family members were seen if a cough illness of >14 days was reported. "
04/01/1994 - "In conjunction with a pertussis vaccine efficacy trial in Germany, nasopharyngeal specimens were collected from May, 1992, to March, 1993, from patients with cough illnesses. "
10/01/2006 - "Between 1 January and 30 June 2005 we performed serological investigations in 139 children presenting with an irritable cough or after application of an acellular pertussis vaccine. "
08/01/2005 - "Pertussis vaccine doses among case children were counted as valid if they were received > or =14 days before the cough onset date ("valid period"). "
|4.||Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)
|8.||Tetanus Toxoid (Vaccine, Tetanus)
|4.||Neonatal Intensive Care